BMS-986187

A pharmaceutical compound

BMS-986187
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

BMS-986187 is a pharmaceutical compound developed by Bristol-Myers Squibb as a selective modulator of the beta-adrenergic receptor. It is primarily investigated for its potential therapeutic effects in cardiovascular diseases.

Mechanism of Action

BMS-986187 functions as a positive allosteric modulator of the beta-adrenergic receptor, specifically targeting the beta-1 adrenergic receptor subtype. This modulation enhances the receptor's response to endogenous catecholamines such as epinephrine and norepinephrine, which are critical in the regulation of cardiac function. By selectively enhancing the activity of the beta-1 adrenergic receptor, BMS-986187 aims to improve cardiac output and efficiency without the broad activation of other adrenergic receptors that can lead to adverse effects.

Pharmacological Effects

The primary pharmacological effect of BMS-986187 is the potentiation of cardiac contractility, which can be beneficial in conditions such as heart failure where the heart's pumping ability is compromised. Unlike traditional beta-adrenergic agonists, BMS-986187 does not directly activate the receptor but instead increases the receptor's sensitivity to its natural ligands. This approach is hypothesized to offer a more controlled enhancement of cardiac function with a reduced risk of tachycardia and arrhythmias.

Clinical Development

BMS-986187 is currently in the investigational stages of clinical development. Early studies focus on its safety, tolerability, and pharmacokinetics in healthy volunteers and patients with heart failure. The compound's ability to improve cardiac function without significant side effects is a key area of interest.

Potential Applications

The selective modulation of the beta-1 adrenergic receptor by BMS-986187 presents potential applications in the treatment of various cardiovascular conditions, including:

• Heart failure
• Cardiomyopathy
• Ischemic heart disease

Challenges and Considerations

While BMS-986187 shows promise, there are challenges in its development. The specificity of receptor modulation must be carefully balanced to avoid off-target effects. Additionally, long-term studies are necessary to fully understand the implications of chronic beta-1 adrenergic receptor modulation.

Related Pages

• Beta-adrenergic receptor
• Heart failure
• Bristol-Myers Squibb